Rhizome AI
AI assistant that answers FDA and EMA regulatory questions from public filings.
On the record
Checkpoint: Watch for Clarivate or IQVIA announcing a low-end self-serve SKU aimed at small biotech
The call
Rhizome sits in the price gap below Clarivate and IQVIA, a gap either could close with one new pricing tier.
Rhizome AI sells software that uses artificial intelligence to help small biotech companies and consultants find and understand regulatory filings for drug development. It is not hard to copy or replace because the company pulls all its information from public documents that anyone can access, and large competitors like Clarivate (a major data company that already serves big pharma) and IQVIA (another drug industry giant) have already built their own AI tools to do almost the same thing. Rhizome survives right now only because it charges much less money (around $4,000 per year versus $20,000 or more) and reaches customers that the big companies ignore. The one thing that could change everything is if Clarivate or IQVIA decide to offer a cheap version of their own tools to those small customers, which would likely happen within the next year or two.
Why
01
AI pressure: Cortellis AI Assistant / Claude via Model Context Protocol. Same public filings, same retrieval trick: Clarivate's AI now answers the questions Rhizome was built to answer. Could AI do the core job? Yes, likely.
02
Bigger players: Clarivate (Cortellis) and IQVIA (IQVIA.ai). Both incumbents ship AI regulatory assistants covering 80+ markets, dwarfing Rhizome's footprint and pricing power. Could a giant copy it? Yes, easily.
03
What protects it. A price gap: Rhizome runs near $4K a year for small biotech and consultants who can't justify Cortellis at $20K+ a seat.
What would change this call
Clarivate or IQVIA launches a self-serve tier priced $4K-$8K within 6-12 months. Would remove Rhizome's low-price niche and directly contest its only buyer segment.
Rhizome closes a priced seed round in the next 6-12 months with named investors. Would show outside investors believe the pricing wedge still holds against Clarivate and IQVIA.
Rhizome's claimed 20+ customers stay active a year after Cortellis Claude integration and IQVIA.ai rollout. Would show retention despite big rivals offering AI-native alternatives to the same buyers.
Rhizome closes a priced seed round in the next 6-12 months with named investors. Would show outside investors believe the pricing wedge still holds against Clarivate and IQVIA.
Rhizome's claimed 20+ customers stay active a year after Cortellis Claude integration and IQVIA.ai rollout. Would show retention despite big rivals offering AI-native alternatives to the same buyers.
Key numbers
- Cortellis AI Assistant went fully GA to all customers
- Rhizome claims 2,800+ answers and 20+ customers
- Legacy reg-intel seats run $20K+/year vs Rhizome's ~$4K
Named risks
- No exclusive data moat, dataset built entirely from public FDA/EMA filings replicable by incumbents.
- Clarivate and IQVIA already shipped competing AI assistants into the same buyer workflow.
- Only ~$590K raised total against well-funded incumbents building similar AI features.
- Traction claims (2,800+ answers, 20+ customers) are vendor-supplied and unverified by third parties.
- Data conflation with unrelated climate-tech Rhizome and nonprofit Rhizome.org obscures true financial picture.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Clarivate (Cortellis) | losing to | GA AI Regulatory Assistant Dec 2025; Claude/MCP integration Mar 2026 vs Rhizome's ~$590K funding |
| IQVIA | losing to | IQVIA.ai agentic platform rollout targeting same regulatory-intelligence workflow through 2026 |
Questions people ask
- Is Rhizome AI profitable in 2026?
- No profitability data is disclosed. Rhizome AI has raised only about $590K total (per CB Insights, May 2026), with the latest $500K convertible note closing around January 2026, and reports 20+ customers, but no revenue or profit figures are independently confirmed.
- Could AI replace Rhizome AI?
- Yes, ironically. Rhizome's own product automates FDA/EMA document research, but it faces the same threat: Clarivate's Cortellis AI Assistant went GA in December 2025 and added Claude via Model Context Protocol in March 2026, offering similar AI-driven retrieval at larger scale.
- Who is Rhizome AI's biggest competitor?
- Clarivate's Cortellis Regulatory Intelligence, covering 80+ markets and 300,000+ documents, is the dominant incumbent. It shipped an AI Regulatory Assistant to GA in December 2025 and integrated Anthropic's Claude in March 2026, directly overlapping Rhizome's niche.
- Who owns Rhizome AI?
- Rhizome AI is privately held, founded in 2023 by solo founder Chetan Mishra, and backed by Y Combinator (W26 batch, partner Tyler Bosmeny) and Cure by Deerfield, a Middle East health accelerator, per CB Insights data from May 2026.
- How much funding has Rhizome AI raised?
- Rhizome AI has raised approximately $590K total via seed and convertible-note structures, with the most recent $500K convertible note closing around late January 2026, according to CB Insights (May 16, 2026). No priced valuation has been disclosed.
- What does Rhizome AI actually do?
- Rhizome AI builds an AI regulatory intelligence platform for life sciences companies. Its core product, Rhizome Ask, answers regulatory questions with citation-backed retrieval drawn from public FDA, EMA, Health Canada, Swissmedic, MHRA, and TGA data, launched publicly via Y Combinator in January 2026.
Timeline
- 2026-06-22IQVIA details IQVIA.ai agentic platform rollout targeting regulatory intelligence workflows
- 2026-05-23Rhizome AI posts Founding Full Stack AI Engineer role, $60K-$120K plus 0.5-2% equity
- 2026-03Clarivate integrates Cortellis Regulatory Intelligence with Anthropic Claude via Model Context Protocol
- 2026-01-29Rhizome AI publicly launches via Y Combinator's Launch YC
- 2026-01Rhizome AI closes $500K convertible note
- 2026-01FDA and EMA jointly publish Guiding Principles for AI in Medicines Development
- 2025-12Clarivate's Cortellis AI Regulatory Assistant reaches general availability for all customers
- 2025-08Clarivate's Cortellis AI Regulatory Assistant enters beta
- 2023Rhizome AI founded by solo founder Chetan Mishra
Revision history
27 July 2026
First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Cortellis Regulatory Intelligence AI-Powered Software (2026-07-07)
- Cortellis Explained: A Guide to the Life Sciences Platform (2026-04-12)
- From Documents to Decisions: How Agentic AI Transforms Regulatory Intelligence (2026-06-22)
- Human-at-the-Helm: Agentic AI for Regulatory Affairs (2026-04-14)
- Products, Competitors, Financials, Employees, Headquarters Locations (2026-05-16)
- Launch YC: Rhizome AI - Know what the FDA thinks (2026-01-29)
- Always know what the FDA thinks (2026-06-01)
- Cure Member Spotlight: Chetan Mishra, Rhizome AI (2026-06-01)
- Claude's Corner: Rhizome AI, The FDA Whisperer for Biotech (2026-06-24)
- Introduction (2026-02-06)
- Founding Full Stack AI Engineer at Rhizome AI (2026-05-23)
- Rhizome AI - Biotech - Reviews & Alternatives (2026-07-23)